BLA 125511 · Nps Pharms INC
Natpara
Parathyroid Hormone · Injection
NovelOrphanLast checked: Nov 20, 2026Latest source record: Apr 7, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Jan 23, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
327
86 Phase 3, 16 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 23, 2015 Original approval · Type 1 - New Molecular Entity NovelOrphanOtherSummary ReviewMedication Guide
4 products under this application
- NATPARA · PARATHYROID HORMONE 75MCG · INJECTABLE, INJECTION · Prescription · TE TBD
- NATPARA · PARATHYROID HORMONE 25MCG · INJECTABLE, INJECTION · Prescription · TE TBD
- NATPARA · PARATHYROID HORMONE 100MCG · INJECTABLE, INJECTION · Prescription · TE TBD
- NATPARA · PARATHYROID HORMONE 50MCG · INJECTABLE, INJECTION · Prescription · TE TBD
Clinical trials
Interventional ClinicalTrials.gov studies with "Parathyroid Hormone" as an intervention, any sponsor and status, largest first.
- TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal OsteoporosisPivotal-lookingCompleted
ShireTakeda (TAK)
NCT00172081 · 2,532 participants · Start Apr 27, 2000 · Primary completion Nov 7, 2003
Drug: placebo; ALX1-11 · For: Osteoporosis
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 174 sites in all
- Study of the Key Techniques of Prevention and Treatment of Osteoporotic RefracturePivotal-lookingRecruiting
Peking Union Medical College HospitalAcademic, hospital or other
NCT05866029 · 2,478 participants (planned) · Start May 26, 2023 · Primary completion Sep 30, 2026
Drug: Denosumab; Teriparatide · For: Osteoporotic Fractures
Sites: Beijing, China; Changchun, China; Changsha, China · 58 sites in all
- Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal WomenPivotal-lookingCompleted
Radius Health, Inc.Industry
NCT01343004 · 2,463 participants · Start Apr 2011 · Primary completion Oct 2014
Drug: Placebo; BA058 80 mcg and 1 more · For: Osteoporosis; Postmenopausal Osteoporosis
Sites: Lakewood, Colorado; Miami, Florida; North Miami, Florida · 28 sites in all
- Antimicrobial Prophylaxis in Thyroid and Parathyroid SurgeryPivotal-lookingCompleted
Ito HospitalAcademic, hospital or other
NCT01805856 · 2,164 participants · Start Nov 2010 · Primary completion May 2012
Drug: PIPC piperacillin sodium; CEZ, cefazolin sodium · For: Thyroid Disease; Parathyroid Disease
Sites: Tokyo, Japan
- Open Label Extension Study of PREOSPivotal-lookingCompleted
ShireTakeda (TAK)
NCT00172133 · 1,683 participants · Start Oct 16, 2001 · Primary completion Apr 13, 2005
Drug: ALX1-11 (drug) · For: Osteoporosis
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 132 sites in all
- Effects of Teriparatide in the Treatment of Postmenopausal Women With OsteoporosisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00670501 · 1,637 participants · Start Aug 1996 · Primary completion Apr 1999
Drug: teriparatide; teriparatide and 3 more · For: Osteoporosis, Postmenopausal
Sites: Boston, Massachusetts; Capital Federal, Argentina; Nedlands, Australia · 17 sites in all
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00001277 · 1,553 participants · Start Dec 15, 1993 · Primary completion Mar 11, 2020
Drug: 68Ga-Dotatate; 18F-DOPA · For: Hyperparathyroidism; Hypercalcemia; Parathyroid Neoplasm and 2 more
Sites: Bethesda, Maryland
- VERtebral Fracture Treatment Comparisons in Osteoporotic WomenPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01709110 · 1,366 participants · Start Oct 2012 · Primary completion Jul 2016
Drug: Teriparatide; Risedronate and 3 more · For: Postmenopausal Osteoporosis
Sites: Birmingham, Alabama; Concord, California; Fresno, California · 103 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
Händel MN, Cardoso I, von Bülow C, et al. · BMJ 2023 · Systematic Review, Network Meta-Analysis
- Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial.
Clarke BL, Khan AA, Rubin MR, et al. · J Clin Endocrinol Metab 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Lithium toxicity profile: a systematic review and meta-analysis.
McKnight RF, Adida M, Budge K, et al. · Lancet 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial.
Khan AA, Rubin MR, Schwarz P, et al. · J Bone Miner Res 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ye Z, Silverberg SJ, Sreekanta A, et al. · J Bone Miner Res 2022 · Meta-Analysis, Systematic Review
- Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis.
Yeung WG, Palmer SC, Strippoli GFM, et al. · Am J Kidney Dis 2023 · Systematic Review, Meta-Analysis
Sponsor: Nps Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.